Last reviewed · How we verify
Roscovitine
At a glance
| Generic name | Roscovitine |
|---|---|
| Also known as | Seliciclib, CYC202 |
| Sponsor | University Hospital, Brest |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors (Phase 1)
- A Phase II, Dose Ranging, Multicenter, Double-blind, Placebo Controlled Study to Evaluate Safety and Effects of (R)-Roscovitine in Adults Subjects With Cystic Fibrosis, Carrying 2 Cystic Fibrosis Caus (Phase 2)
- A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease (Phase 2)
- A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer (Phase 2)
- Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine (Phase 2)
- A Phase I With Dose Expansion to Determine the Maximum Tolerated Dose of Liposomal Doxorubicin in Combination With Seliciclib for the Treatment of Patients With Metastatic Triple Negative Breast Cance (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |